Enhancing the Antitumor Effect of Doxorubicin with Photosensitive Metal-Organic Framework Nanoparticles against Breast Cancer.


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
02 08 2021
Historique:
pubmed: 3 7 2021
medline: 21 1 2022
entrez: 2 7 2021
Statut: ppublish

Résumé

Breast cancer is one of the most common malignant tumors in women. The existence of multiple breast cancer subtypes often leads to chemotherapy failure or the development of drug resistance. In recent years, photodynamic therapy has been proven to enhance the sensitivity of tumors to chemotherapeutic drugs. Porphyrin-based metal-organic framework (MOF) materials could simultaneously be used as carriers for chemotherapy and photosensitizers in photodynamic therapy. In this paper, doxorubicin hydrochloride (DOX) was loaded in porphyrin MOFs, and the mechanism of the synergistic effect of the DOX carriers and photodynamic therapy on breast cancer was investigated. In vitro and in vivo experiments have shown that MOFs could prolong the residence time of DOX in tumor tissues and promote the endocytosis of DOX by tumor cells. In addition, adjuvant treatment with photodynamic therapy can promote breast cancer tumors to resensitize to DOX and synergistically enhance the chemotherapy effect of DOX. Therefore, this study can provide effective development ideas for reversing drug resistance during breast cancer chemotherapy and improving the therapeutic effect of chemotherapy on breast cancer.

Identifiants

pubmed: 34213912
doi: 10.1021/acs.molpharmaceut.1c00249
doi:

Substances chimiques

Antibiotics, Antineoplastic 0
Metal-Organic Frameworks 0
Nanoparticle Drug Delivery System 0
Photosensitizing Agents 0
Porphyrins 0
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3026-3036

Auteurs

Qianqian Jiang (Q)

School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China.

Mengmeng Zhang (M)

School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China.

Quanwei Sun (Q)

School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China.

Dengke Yin (D)

School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China.
Anhui Provincial Key Laboratory of Research & Development of Chinese Medicine, Hefei 230021, China.
Key Laboratory of Xin'an Medicine, Ministry of Education, Hefei 230038, China.

Zihua Xuan (Z)

School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China.

Ye Yang (Y)

School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230031, China.
Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei 230031, China.
Key Laboratory of Xin'an Medicine, Ministry of Education, Hefei 230038, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH